In addition to demonstrating its many current point-of-care diagnostics products, such as Quo-Lab and Quo-Test HbA1c analysers, EKF DIAGNOSTICS will be highlighting two novel diagnostic tests at Medica.
A new test kit for soluble tumour necrosis factor receptor 1 (sTNFR1) identifies diabetic patients at high risk of end stage renal disease (ESRD), up to 10 years in advance of previous tests. Based on a standard ELISA, the test detects circulating levels of sTNFR1 in just 4.5 hours. Early diagnosis leads to improved patient outcome and reduced healthcare costs, so the test is currently undergoing extensive validation throughout Europe. With up to 40% of first time births leading to dysfunctional labour, EKF Diagnostics has also developed a test that indicates whether birth intervention is required to ensure safe delivery. The new test uses proprietary sensor technology to test lactate levels in amniotic fluid, and is currently being trialled in a 5,000 patient multi-centre study. The company is exhibiting in Hall 3, Stand C70.
